An HIV drug could stop one of the early changes in skin cancer cells that leads to them becoming resistant to treatment, according to a Cancer Research UK-funded study published in Cancer Cell*.
MRV Research
‘Nano-sensing’ drives melanoma cells’ invasion
A new study sheds light on how melanoma cells change from benign to malignant, and how the complex interaction between the cells and their surrounding environment affects outcomes of the cancer.
Link found between gene and melanoma growth
Yale researchers have identified a link between a gene associated with melanoma and the disease’s growth that may signal an avenue for new treatments.
Beyond BRAF: Emerging Agents Aim at Other Melanoma Targets
Targeted therapy for melanoma is much more than just BRAF inhibition.
While more than half of cutaneous melanoma tumors are BRAF-positive, agents that target the other 3 subtypes—RAS mutant, NF1 mutant, and triple wild-type—identified by the Cancer Genome Atlas (TCGA) in 2015 now have the increasing potential to improve survival for non-BRAF patients, says Jason Luke, MD, an assistant professor of Medicine at the University of Chicago Medicine.